Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

768.99 +3.31 (+0.43%)
Streaming Delayed Price Updated: 12:28 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Elanco (ELAN) Q4 Earnings Report Preview: What To Look For
Animal health company Elanco (NYSE:ELAN) will be announcing earnings results tomorrow before market open. Here’s what to look for. 
Via StockStory
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
Unlocking the high Growth Potential of NYSE:LLY.
ELI LILLY & CO (NYSE:LLY) is a candidate for high growth investors. Here's why. Full fundamental and technical analysis of (NYSE:LLY). 
Via Chartmill
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Via The Motley Fool
Eli Lilly's Options Frenzy: What You Need to Know
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
Via Benzinga
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Via The Motley Fool
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs. 
Via Benzinga
Topics Government
Exposures Political
3 Magnificent Growth Stocks to Buy Right Now
Via The Motley Fool
In Flight Dining
UNH is trimming its losses, 95% of the reason I didn’t take instant triple-digit profits is because the Wing Sting is so severe. United Healthcare is FAR from being done getting smashed in the face. 
Via Talk Markets
Topics Stocks / Equities
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
The FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved. 
Via Investor's Business Daily
Exposures Product Safety
Eli Lilly (LLY): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Eli Lilly’s stock price fell to $872.91. Shareholders have lost 8.3% of their capital, which is disappointing considering the S&P 500 has climbed by 8.9%. This might have... 
Via StockStory
Topics Stocks
Exposures US Equities
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management. 
Via Stocktwits
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
Biogen Stock Is Mutating Into a Value Play
Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X 
Via MarketBeat
Digesting Super Bowl Ads, Dunkin' & Starbucks Plans, and Some Weight Loss Drug News
The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime. 
Via The Motley Fool
Digging Into What Hershey and Eli Lilly Told Investors
Via The Motley Fool
Hims & Hers Earnings Could Be a Game Changer—What to Do Now
After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements. 
Via MarketBeat
3 Hot Stocks That Have Already Doubled in 2025
It may be early, but some blazing investments have already delivered wealth-altering gains in this young year. 
Via The Motley Fool
Hims & Hers Stock Is On Fire, But Is It a Bubble?
The stock isn't as expensive as you might think. 
Via The Motley Fool
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management. 
Via Benzinga
Exposures Product Safety
Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4
Billionaire investor Stanley Druckenmiller's family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent... 
Via Benzinga
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally. 
Via Benzinga
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low? 
Via MarketBeat
3 Stocks That Could Trounce the Market in 2025
Via The Motley Fool
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
Via The Motley Fool
MarketBeat Week in Review – 02/10 - 02/14
Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in 
Via MarketBeat
Topics Credit Cards Economy Government
Exposures Interest Rates Political Tariff
Top Stock Reports For Apple, Eli Lilly & Shopify
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Eli Lilly and Co., and Shopify Inc., as well as a micro-cap stock ImmuCell Corp. 
Via Talk Markets
Topics Stocks / Equities
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster. 
Via MarketBeat
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.